Company / Operating Cash Flow per Share
Fulcrum Therapeutics, Inc. Operating Cash Flow per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$948.07
FY2025
5-year range
-$2219.34 / -$35.78
FY2021-FY2025
Trend
-2549.5%
vs FY2024
Sector context
#211 of 212
Health Care
What the data says
Operating Cash Flow per Share changed -2549% YoY in FY2025, a notable deviation from the 7-year average annual change of -329%.
Based on SEC 10-K filings.
-948.07 in FY2025.
Improved from $-1483.69 to $-948.07 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 212This company -$948.07 Sector average -$14.72
▼
-6339.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 2549.5% year-over-year.
- Ranks #211 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2024.
- Lowest operating cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$948.07 | -2549.5% |
| FY2024 | -$35.78 | +97.6% |
| FY2023 | -$1483.69 | +31.2% |
| FY2022 | -$2157.10 | +2.8% |
| FY2021 | -$2219.34 | -4.9% |
| FY2020 | -$2116.23 | +40.8% |
| FY2019 | -$3574.42 | +80.1% |
| FY2018 | -$17949.09 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026